Abstract:Progressive supranuclear palsy (PSP) is an atypical form of parkinsonism characterized by tauopathy, manifesting as oculomotor dysfunction, postural instability, akinesia, and cognitive/language impairments. The diagnosis and examination of PSP can be challenging, primarily due to the unclear and underexplored pathomechanisms involved, alongside absence of effective treatments. Clinical variants of PSP is the second most common form of neurodegenerative parkinsonism after Parkinson's disease (PD). It is defined by a symmetrical akinetic-rigid syndrome (atypical parkinsonism) and vertical supranuclear gaze palsy. In contrast to PD, PSP often presents with gait instability, backward falls, and cognitive and behavioral changes at early disease stages. The classification of PSP has evolved since Richardson, Steele, and Olszewski's initial reporting of the condition in 1963, which included a cohort of nine patients. Over the years, the definition of this disorder has evolved to encapsulate a group of patients with distinct clinical variants, notably the classical Richardson syndrome (RS) and several atypical phenotypes, each with significant implications for disease progression and quality of life (QoL). The 2017 Movement Disorder Society Diagnostic Criteria by Hoglinger et al., improved the sensitivity for detecting early and variant PSP presentations and provided more specific differential diagnoses for conditions such as PD and other forms of atypical parkinsonian syndromes. Owing to the growing interest in the disease's progression, evaluating the QoL for patients with PSP has become crucial. This review emphasizes the significance of QoL evaluation and its feasibility for practical implications, serving as an initial foundation for future research focused on the well-being of individuals affected by PSP. Progressive supranuclear palsy (PSP) is an atypical form of parkinsonism characterized by tauopathy, manifesting as oculomotor dysfunction, postural instability, akinesia, and cognitive/language impairments. Diagnosing PSP is challenging owing to the lack of tools for differential examination. Additionally, the pathomechanism of this disease is not sufficiently understood, and no treatment is currently available. Owing to the growing interest in the disease's progression, evaluating the quality of life (QoL) for patients with PSP has become crucial. This review emphasizes the significance of QoL evaluation and its feasibility for practical implications, serving as an initial foundation for future research focused on the well-being of individuals affected by PSP.

Longitudinal change of energy expenditure, body composition and dietary habits in Progressive Supranuclear Palsy patients

Cardiovascular Autonomic Dysfunction is Associated with Executive Dysfunction and Poorer Quality of Life in Progressive Supranuclear Palsy-Richardson’s Syndrome

Six-Year Follow-Up of Dysphagia in Patients with Parkinson’s Disease

Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy

Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy

Progressive Supranuclear palsy (PSP) disease progression, management, and healthcare resource utilization: a retrospective observational study in the US and Canada

Dysphagia Prevalence in Progressive Supranuclear Palsy: A Systematic Review and Meta-Analysis

Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials

Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis

Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies

Phenotypic spectrum of Progressive Supranuclear Palsy: Clinical study and APOE effect

Retinal Thinning as a Marker of Disease Severity in Progressive Supranuclear Palsy

Peripheral immune profile and neutrophil‐to‐lymphocyte ratio in progressive supranuclear palsy: Case–control study and meta‐analysis

Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory

Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants

Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice

The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy

Clinical and MRI analysis of progressive supranuclear palsy：a report of 12 cases

Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life

Sleepless Night and Day, the Plight of Progressive Supranuclear Palsy

The Lived Experiences of People with Progressive Supranuclear Palsy and Their Caregivers